caa a22 4500 469079681 CHVBK 20180323132946.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF00168947 doi (NATIONALLICENCE)springer-10.1007/BF00168947 Systemic administration of baclofen and the GABAB antagonist, CGP 35348, does not affect GABA, glutamate or aspartate in microdialysates of the striatum of conscious rats [Elektronische Daten] [P. Waldmeier, K. Stöcklin, J.-J. Feldtrauer] Summary: Previous in vitro experiments have shown that the GABAB agonist, baclofen, and the antagonist, CGP 35348, respectively, decrease and increase the autoreceptor-mediated release of GABA in brain slices and synaptosomes. Since it is not clear whether these autoreceptors are operative in vivo, an attempt was made to reproduce these results in brain dialysis experiments, knowing that only positive results would permit a conclusion in view of the doubts expressed in the literature with respect to the origin of extracellular GABA. Because of older reports of an inhibitory action of baclofen on the in vitro release of glutamate, which might be ascribed to the action of presynaptic GABAB heteroreceptors, extracellular glutamate and aspartate were also measured. Neither (−)-baclofen, administered systemically at a dose of 20 mg/kg i.p., nor the GABAB antagonist, CGP 35348 (300 mg/kg i.p.) had significant effects on basal overflow of GABA, glutamate, or aspartate nor on that evoked by 100 mmol/l K+ in the striatum of the conscious, freely moving rat. To ascertain this result, (−)-baclofen was also administered between two K+ stimulations, so that the first stimulation could serve as an intraindividual control of the second. The compound did not significantly affect K+ evoked overflow of any of the three transmitter amino acids under these conditions. It must be emphasized that these data do not exclude the operativity of presynaptic GABAB auto- and hetero-receptors in vivo. They only suggest that this question must, in all probability, be addressed by other techniques than brain dialysis. Springer-Verlag, 1992 Baclofen nationallicence CGP 35348 nationallicence Extracellular GABA nationallicence Extracellular glutamate nationallicence Extracellular aspartate nationallicence Brain dialysis nationallicence Waldmeier P. Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Switzerland aut Stöcklin K. Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Switzerland aut Feldtrauer J.-J Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Switzerland aut Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 345/5(1992-05-01), 548-552 0028-1298 345:5<548 1992 345 210 https://doi.org/10.1007/BF00168947 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00168947 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Waldmeier P. Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Switzerland aut NATIONALLICENCE 700 1- Stöcklin K. Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Switzerland aut NATIONALLICENCE 700 1- Feldtrauer J.-J Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Switzerland aut NATIONALLICENCE 773 0- Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 345/5(1992-05-01), 548-552 0028-1298 345:5<548 1992 345 210 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer